Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, Tsiami, Styliani, Vijayan, Sooraj, Jung, Haewon, Barkham, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777045/
https://www.ncbi.nlm.nih.gov/pubmed/35079380
http://dx.doi.org/10.1002/ccr3.5205
_version_ 1784636975750316032
author Baraliakos, Xenofon
Tsiami, Styliani
Vijayan, Sooraj
Jung, Haewon
Barkham, Nick
author_facet Baraliakos, Xenofon
Tsiami, Styliani
Vijayan, Sooraj
Jung, Haewon
Barkham, Nick
author_sort Baraliakos, Xenofon
collection PubMed
description The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT‐P13 SC.
format Online
Article
Text
id pubmed-8777045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87770452022-01-24 Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series Baraliakos, Xenofon Tsiami, Styliani Vijayan, Sooraj Jung, Haewon Barkham, Nick Clin Case Rep Case Report The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT‐P13 SC. John Wiley and Sons Inc. 2022-01-20 /pmc/articles/PMC8777045/ /pubmed/35079380 http://dx.doi.org/10.1002/ccr3.5205 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Baraliakos, Xenofon
Tsiami, Styliani
Vijayan, Sooraj
Jung, Haewon
Barkham, Nick
Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title_full Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title_fullStr Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title_full_unstemmed Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title_short Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
title_sort real‐world evidence for subcutaneous infliximab (ct‐p13 sc) treatment in patients with psoriatic arthritis during the coronavirus disease (covid‐19) pandemic: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777045/
https://www.ncbi.nlm.nih.gov/pubmed/35079380
http://dx.doi.org/10.1002/ccr3.5205
work_keys_str_mv AT baraliakosxenofon realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithpsoriaticarthritisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT tsiamistyliani realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithpsoriaticarthritisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT vijayansooraj realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithpsoriaticarthritisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT junghaewon realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithpsoriaticarthritisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT barkhamnick realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithpsoriaticarthritisduringthecoronavirusdiseasecovid19pandemicacaseseries

Ejemplares similares